<DOC>
	<DOCNO>NCT00066716</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Celecoxib may increase effectiveness chemotherapy drug make tumor cell sensitive drug . Celecoxib may also stop growth tumor cell stop blood flow tumor and/or may block enzyme necessary growth . Combining celecoxib paclitaxel carboplatin surgery may shrink tumor remove surgery . Giving celecoxib alone surgery may kill remain tumor cell . PURPOSE : This phase II trial study well give celecoxib together paclitaxel carboplatin work treat patient undergo surgery esophageal cancer .</brief_summary>
	<brief_title>Celecoxib , Paclitaxel , Carboplatin Treating Patients With Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate complete pathological response and/or minimal residual microscopic disease patient squamous cell adenocarcinoma esophagus treat preoperative celecoxib , paclitaxel , carboplatin . Secondary - Determine clinical response rate patient treat regimen . - Determine chemotherapy-related toxicity regimen patient . - Determine time progression , disease-free survival , overall survival patient treat regimen . OUTLINE : Patients receive paclitaxel IV 3 hour carboplatin IV 1 hour day 1 , 22 , 43 . Patients also receive oral celecoxib twice daily begin 3-7 day first dose chemotherapy continue morning plan surgical resection ( day 64 71 ) . Approximately 28-56 day resection , patient may resume oral celecoxib twice daily continue 1 year absence disease progression unacceptable toxicity . Patients follow periodically 18 month surgery . PROJECTED ACCRUAL : A total 39 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal cancer 1 follow cellular type : Squamous cell Adenocarcinoma Potentially resectable disease No distant metastases PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 80100 % Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 No bleed disorder Hepatic Bilirubin normal AST ALT less 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal Creatinine great 2.0 mg/dL Cardiovascular No significant history unstable cardiovascular disease No inadequately control hypertension No angina No myocardial infarction within past 6 month No ventricular cardiac arrhythmia require medication No congestive heart failure would preclude study therapy Pulmonary Pulmonary function acceptable surgery No interstitial pneumonia No interstitial fibrosis Gastrointestinal No history peptic ulcer disease No irritable bowel syndrome No inflammatory bowel disease No chronic diarrhea No bowel obstruction within past 5 year Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity allergic reaction COX2 inhibitor , sulfonamide , NSAIDs , salicylates No hypersensitivity paclitaxel carboplatin No serious underlie medical condition would preclude study therapy No significant psychiatric illness would preclude study compliance No uncontrolled diabetes mellitus No uncontrolled infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No concurrent chronic steroid use except inhaled mometasone fluticasone Radiotherapy Not specify Surgery Not specify Other More 3 week since prior clinical trial therapy At least 72 hour since prior nonsteroidal antiinflammatory drug ( NSAIDs ) No concurrent chronic NSAID use ( 7 day continuous therapy per month OR 3 day therapy per week ) No concurrent investigational agent No concurrent enzymeinducing anticonvulsant ( e.g. , phenytoin phenobarbital ) No concurrent cyclooxygenase ( COX ) 2 inhibitor No concurrent lithium fluconazole Concurrent lowdose aspirin ( 325 mg/day less ) allow cardiovascular prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer ( lymph node metastasis )</keyword>
</DOC>